・ 科学雑誌編集者・出版社への申立て
申立てPart.1, 申立てPart.2, 申立てPart.3, 申立てPart.4
・ 申立てに対する、科学雑誌編集者・出版社からの返信メール
返信Part.1、返信Part.2、返信Part.3
American Journal of Hypertension誌からの返信メール
件名
RE: Allegations of fabrication and falsification (Am J Hypertens. 2008;21:451-7)
送信者
Yvonne P Raiford
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
日時
2011年02月04日 01:13:11
Dear Dr. Jigen,
Thank you for your letter. We are looking into this matter.
Best regards,
Yvonne Raiford
Managing Editor
American Journal of Hypertension
________________________________________
From: Juuichi Jigen [11jigen@mail.goo.ne.jp]
Sent: Thursday, February 03, 2011 5:22 AM
To: Yvonne P Raiford
Subject: Allegations of fabrication and falsification (Am J Hypertens. 2008;21:451-7)
Dear Dr.Raiford (Managing Editor of American Journal of Hypertension),
Please investigate fraudulent data of the article “Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.” By Suzuki K, Uchida K, Nakanishi N, Hattori Y., published in American Journal of Hypertension (2008 Apr;21(4):451-7.). You can find fabricated (falsified) Figure 1(a),(b) : namely,
(1)
The first, second and third bands from right of IkB-alpha image, top-panel in Figure 4(A) of Ref.2 is similar to the second, third and fourth bands from left of pAMPK image in Figure 1(A) of Ref.2.
Moreover, the first and second bands from left of IkB-alpha image, top-panel in Figure 4(A) of Ref.2 is similar to both the fifth and sixth bands from left of pAMPK image in Figure 1(A) of Ref.2
and the fifth and sixth bands from left of pAMPK image in Figure 1(a) of Ref.4..
Furthermore, the pAMPK image (all 7 bands) in Figure 1(A) of Ref.2 is similar to the pAMPK image (all 7 bands) in Figure 1(a) of Ref.4
,and first to sixth bands from left of the above pAMPK image of Ref.2,9 are similar to the pAMPK image for cilostazol in Figure 1(D) of Ref.2
and the pAMPK image in Figure 2(A) of Ref.1
and the pAMPK image for Metformin in Figure 3(b) of Ref.3.
In addition, the rightside 5 bands (2.5 min 〓 60 min) of the pAMPK imgae in Figure 2(A) of Ref.1 are similar to upside-down and left-right reversal of the pAMPK image in Figure 3(A) of Ref.1.
(2)
The AMPK image in Figure 1(A) of Ref.2 is similar to the APMK image in Figure 1(a) of Ref.4.
Moreover, the leftside 6 bands of these two APMK image are similar to the AMPK image in Figure 2(A) of Ref.1.
Furthermore, rightside 5 bands of this AMPK image in Figure 2(A) of Ref.1 are similar to the pAMPK image for Milrinone in Figure 1(D) of Ref.2
(3)
The rightside 5 bands of the AMPK image in Figure 1(B) of Ref.2 is similar to both the AMPK image in Figure 2(B) of Ref.1 and the AMPK image in Figure 1(b) of Ref.4.
Likewise, 5 bands (second to sixth bands from left) of pAMPK image in Figure 1(B) of Ref.2 are similar to the pAMPK image in Figure 2(B) of Ref.1 and the pAMPK image in Figure 1(b) of Ref.4.
(4)
The ACC and pACC images in Figure 1(A) of Ref.2 are similar to the ACC and pACC images in Figure 1(a) of Ref.4, respectively.
Moreover, the leftside 6 bands of these two images are similar to the ACC and p-ACC images in Figure 2(A) of Ref.1.
__________________
References
1,
J Atheroscler Thromb. 2010;17(5):503-9. Epub 2010 Feb 24.
Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo.
Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K.
2,
Cardiovasc Res. 2009 Jan 1;81(1):133-9. Epub 2008 Aug 14.
Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.
Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S, Satoh H, Akimoto K, Kasai K.
3,
Hypertens Res. 2009 Sep;32(9):765-9. Epub 2009 Jul 10.
Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K.
4.
Am J Hypertens. 2008 Apr;21(4):451-7. Epub 2008 Feb 7.
Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
Suzuki K, Uchida K, Nakanishi N, Hattori Y.
Sincerely yours,
Juuichi Jigen
E-mail: 11jigen@mail.goo.ne.jp
Life Sciences誌からの返信メール
件名
Re: Allegations of fabrication and falsification (Life Sciences 2008;82:884-91).
送信者
Frank Porreca
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
CC
Kanter-Schlifke, Irene (ELS-AMS) ; Kisthardt, Christine K - (kisthdt)
日時
2011年02月04日 00:44:29
Dear Dr. Jigen,
thank-you for bringing this to our attention. We will investigate
this and be back in touch shortly.
Sincerely,
Frank Porreca
At 01:10 AM 2/3/2011, you wrote:
>Dear Dr. Porreca,
>
>Please investigate fraudulent data of the article $B!H(BPPARalpha
>activators upregulate eNOS activity and inhibit cytokine-induced
>NF-kappaB activation through AMP-activated protein kinase
>activation.$B!I(B Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori
>Y., published in Life Sciences (2008 Apr 9;82(15-16):884-91). You
>can find fabricated (falsified) Figure 1(A),(B) and Figure
>5(A),(B),(C) : namely,
>
>(1)
>The Phospho-IkB-alpha image in Figure 4(A) of Ref.2 is similar to
>the Phospho-IkB-alpha image in Figure 5(A) of Ref.3
>and the Phospho-IkBa image in Figure 3(A) of Ref.4
>and the Phospho IkB-alpha image in Figure 6(A) of Ref.5.
>
>(2)
>The IkB-alpha image in Figure 4(B) of Ref.2 is similar to
>the IKB-alpha image in Figure 5(B) of Ref.3
>and the IkBa image in Figure 3(B) of Ref.4
>and the leftside 4 bands of the ONOO-IkB-alpha image in Figure 6(A) of Ref.5.
>
>(3)
>The GST-Ikb-alpha image of top panel in Figure 4(C) of Ref.1 is
>similar to both GST-Ikb-alpha image of top panel in Figure4(C) of
>Ref.2 and IkB-alpha image of top panel in Figure 5(C) of Ref.3
>
>
>(4)
>The IKKalpha/beta image in Figure 4(C) of Ref.2 is similar to both
>the ACC image in Figure 1(A) of Ref.3 and the IKKalpha/beta image in
>Figure 5(C) of Ref.3.
>
>(5)
>The GST-Ikb-alpha image of bottom panel in Figure 4(C) of Ref.2 is
>similar to GST-Ikb-alpha image of bottom panel in Figure4(C) of
>Ref.3. Moreover, these two images are similar to both the left-right
>reversal of the Akt image in Figure 1(A) of Ref.1 and the
>upside-down + left-right reversal of the GST-Ikb-alpha image of
>bottom panel in Figure4(C) of Ref.1
>
>(6)
>The GST-IkB-alpha image, bottom panel in Figure 4(C) of Ref.2 is
>similar to the Akt image in Figure 1(A) of Ref.3.
>
>(7)
>The p-AKT image in Figure 1(A) of Ref.3 is similar to the p-ACC
>image in Figure 1(B) of Ref.3
>
>(8)
>The IkB-alpha image in Figure 5(A) of Ref.3 is similar to both the
>IkB-a image in Figure 3(A) of Ref.4 and the IkB-alpha image in
>Figure 6(A) of Ref.5.
>
>(9)
>The AMPK and pAMPK images in Figure 1(A) of Ref.1 are similar to the
>AMPK and pAMPK images in Figure 1(A) of Ref.3.
>
>(10)
>The p-AKT image in Figure 1(A) of Ref.1 is similar to the p-Akt
>image in Figure 1(A) of Ref.3.
>
>(11)
>The eNOS image in Figure 1(A) of Ref.1 is similar to the eNOS image
>in Figure 1(A) of Ref.3.
>
>
>
>__________________
>
>References
>
>1,
>Metabolism. 2010 Jun 25. [Epub ahead of print]
>Fenofibrate suppresses microvascular inflammation and apoptosis
>through adenosine monophosphate-activated protein kinase activation.
>Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K.
>
>2,
>Cardiovasc Res. 2009 Jan 1;81(1):133-9. Epub 2008 Aug 14.
>Cilostazol inhibits cytokine-induced nuclear factor-kappaB
>activation via AMP-activated protein kinase activation in vascular
>endothelial cells.
>Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S,
>Satoh H, Akimoto K, Kasai K.
>
>3,
>Life Sci. 2008 Apr 9;82(15-16):884-91. Epub 2008 Feb 16.
>PPARalpha activators upregulate eNOS activity and inhibit
>cytokine-induced NF-kappaB activation through AMP-activated protein
>kinase activation.
>Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y.
>
>
>4,
>Hypertension. 2006 Jun;47(6):1183-8. Epub 2006 Apr 24.
>Metformin inhibits cytokine-induced nuclear factor kappaB activation
>via AMP-activated protein kinase activation in vascular endothelial cells.
>Hattori Y, Suzuki K, Hattori S, Kasai K.
>
>
>5,
>Cardiovasc Res. 2004 Jul 1;63(1):31-40.
>NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to
>rationalize cytoprotective and cytotoxic actions attributed to NO.
>Hattori Y, Kasai K, Gross SS.
>
>
>
>Sincerely yours,
>
>Juuichi Jigen
>E-mail: 11jigen@mail.goo.ne.jp
>
>
>
>
>
Biochimica et Biophysica Acta誌からの返信メール
件名
Re: Allegations of fabrication and falsification
送信者
Dennis Vance
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
CC
Jeffrey Keller ; Adriaan FA (ELS-AMS) Klinkenberg
日時
2011年02月03日 01:35:29
添付
J Cardiovasc Pharmacol. 2004 43 209-13.pdf (583k)attach1 (1k)
Dear Dr. Jigen:
Thanks for your email. I have looked at the two figures and agree that the top panels in the two Figures seem to be identical but I am not so sure the bottom panels are the same. I shall write to Dr. Hattori and ask for an explanation. I will let you know his reply and any action we might take.
Sincerely yours,
Dennis Vance, PhD
Distinguished University Professor
Editor-in-Chief, BBA
Scientist of the Alberta Heritage Foundation for Medical Research
Chair, Board of Directors, Deuel Conference on Lipids
Department of Biochemistry and Group on the Molecular and Cell Biology of Lipids
School of Molecular and Systems Medicine
328 Heritage Medical Research Centre
University of Alberta
Edmonton, Alberta T6G 2S2 Canada
phone: 780-492-8286
Fax: 780-492-3383
email: dennis.vance@ualberta.ca
Journal of Cardiovascular Pharmacology誌からの返信メール
件名
Re: RE: Allegations of fabrication and falsification
送信者
Juuichi Jigen <11jigen@mail.goo.ne.jp>
宛先
Emily.Hurd@wolterskluwer.com
添付
BBA2004.pdf (613k)JCP2004.pdf (583k)
Dear Dr. Hurd,
I am sorry for your inconvenience.
Now, I send new attachments.
Please compare Figure 3's top panel of JCP2004 article and Figure 5's top panel of BBA2004 article.
Sincerely yours,
Juuichi Jigen
----- Original Message -----
> Dear Dr. Jigen:
>
> We are not able to open the files attached to this email either. Please
> send new attachments.
>
> Kind Regards,
> Emily Hurd
>
> Emily Hurd
> Managing Editor, Journal of Cardiovascular Pharmacology
> Wolters Kluwer Health Medical Research
>
> tel (978) 979-1111
> emily.hurd@wolterskluwer.com
>
> Confidentiality Notice: This email and its attachments (if any) contain
> confidential information of the sender. The information is intended only
> for the use by the direct addressees of the original sender of this
> email. If you are not an intended recipient of the original sender (or
> responsible for delivering the message to such person), you are hereby
> notified that any review, disclosure, copying, distribution or the
> taking of any action in reliance of the contents of and attachments to
> this email is strictly prohibited. If you have received this email in
> error, please immediately notify the sender at the address shown herein
> and permanently delete any copies of this email (digital or paper) in
> your possession.
>
>
> -----Original Message-----
> From: Juuichi Jigen [mailto:11jigen@mail.goo.ne.jp]
> Sent: Wednesday, February 02, 2011 9:28 AM
> To: Hurd, Emily; Sollenberger, Jennifer; Hee, Laurie
> Subject: Allegations of fabrication and falsification
>
> Please investigate fraudulent data of the article "Disruption of the
> actin cytoskeleton up-regulates iNOS expression in vascular smooth
> muscle cells." by Hattori Y, Kasai K. published in J Cardiovasc
> Pharmacol. (2004 Feb;43(2):209-13.). You can find the fabricated
> (falsified) Figure 3 : namely, Figure 3 of the above article [J
> Cardiovasc Pharmacol. (2004 Feb;43(2):209-13.)] is identical to Figure 5
> of another article [Biochim Biophys Acta. (2004 Aug 4;1689(3):267-72.)].
>
>
> References
> 1
> J Cardiovasc Pharmacol. 2004 Feb;43(2):209-13.
> Disruption of the actin cytoskeleton up-regulates iNOS expression in
> vascular smooth muscle cells.
> Hattori Y, Kasai K.
> http://www.ncbi.nlm.nih.gov/pubmed/14716207
>
> 2
> Biochim Biophys Acta. 2004 Aug 4;1689(3):267-72.
> Statin blocks Rho/Rho-kinase signalling and disrupts the actin
> cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide
> synthesis in vascular smooth muscle cells.
> Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y.
>
Diabetes, Obesity and Metabolism誌からの返信メール
件名
FW: Diab. Obes. Metab. 2009; 11: 143-149
送信者
Susan Lane
宛先
11jigen@mail.goo.ne.jp
日時
2011年02月03日 23:11:21
From: Richard Donnelly [mailto:Richard.Donnelly@nottingham.ac.uk]
Sent: 03 February 2011 11:04
To: 11jigen@mail.goo.n.ejp
Cc: Susan Lane
Subject: Diab. Obes. Metab. 2009; 11: 143-149
Dear Dr Jigen:
Thank you for your Email concerning a paper published by Jojima et al in Diab. Obes. Metab.
Research misconduct is something that concerns all of us, but the responsibility for investigating allegations of research misconduct lies with the university that employs the authors and any sponsor that funded the research. Most, if not all, universities have clear internal policies and procedures for investigating allegations of research misconduct.
You should, therefore, direct your concerns to the relevant Dean or principal of Dokkyo University School of Medicine. If the institution, as part of their investigation, requires information from the Journal, I will be happy to assist. Furthermore, the journal would take appropriate action only on the advice of an institutional committee or head, following the conclusion of their internal investigation.
Sincerely:
Prof. Richard Donnelly MD, PhD, FRCP, FRACP
Editor, Diabetes, Obesilty and Metabolism
申立てPart.1, 申立てPart.2, 申立てPart.3, 申立てPart.4
・ 申立てに対する、科学雑誌編集者・出版社からの返信メール
返信Part.1、返信Part.2、返信Part.3
American Journal of Hypertension誌からの返信メール
件名
RE: Allegations of fabrication and falsification (Am J Hypertens. 2008;21:451-7)
送信者
Yvonne P Raiford
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
日時
2011年02月04日 01:13:11
Dear Dr. Jigen,
Thank you for your letter. We are looking into this matter.
Best regards,
Yvonne Raiford
Managing Editor
American Journal of Hypertension
________________________________________
From: Juuichi Jigen [11jigen@mail.goo.ne.jp]
Sent: Thursday, February 03, 2011 5:22 AM
To: Yvonne P Raiford
Subject: Allegations of fabrication and falsification (Am J Hypertens. 2008;21:451-7)
Dear Dr.Raiford (Managing Editor of American Journal of Hypertension),
Please investigate fraudulent data of the article “Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.” By Suzuki K, Uchida K, Nakanishi N, Hattori Y., published in American Journal of Hypertension (2008 Apr;21(4):451-7.). You can find fabricated (falsified) Figure 1(a),(b) : namely,
(1)
The first, second and third bands from right of IkB-alpha image, top-panel in Figure 4(A) of Ref.2 is similar to the second, third and fourth bands from left of pAMPK image in Figure 1(A) of Ref.2.
Moreover, the first and second bands from left of IkB-alpha image, top-panel in Figure 4(A) of Ref.2 is similar to both the fifth and sixth bands from left of pAMPK image in Figure 1(A) of Ref.2
and the fifth and sixth bands from left of pAMPK image in Figure 1(a) of Ref.4..
Furthermore, the pAMPK image (all 7 bands) in Figure 1(A) of Ref.2 is similar to the pAMPK image (all 7 bands) in Figure 1(a) of Ref.4
,and first to sixth bands from left of the above pAMPK image of Ref.2,9 are similar to the pAMPK image for cilostazol in Figure 1(D) of Ref.2
and the pAMPK image in Figure 2(A) of Ref.1
and the pAMPK image for Metformin in Figure 3(b) of Ref.3.
In addition, the rightside 5 bands (2.5 min 〓 60 min) of the pAMPK imgae in Figure 2(A) of Ref.1 are similar to upside-down and left-right reversal of the pAMPK image in Figure 3(A) of Ref.1.
(2)
The AMPK image in Figure 1(A) of Ref.2 is similar to the APMK image in Figure 1(a) of Ref.4.
Moreover, the leftside 6 bands of these two APMK image are similar to the AMPK image in Figure 2(A) of Ref.1.
Furthermore, rightside 5 bands of this AMPK image in Figure 2(A) of Ref.1 are similar to the pAMPK image for Milrinone in Figure 1(D) of Ref.2
(3)
The rightside 5 bands of the AMPK image in Figure 1(B) of Ref.2 is similar to both the AMPK image in Figure 2(B) of Ref.1 and the AMPK image in Figure 1(b) of Ref.4.
Likewise, 5 bands (second to sixth bands from left) of pAMPK image in Figure 1(B) of Ref.2 are similar to the pAMPK image in Figure 2(B) of Ref.1 and the pAMPK image in Figure 1(b) of Ref.4.
(4)
The ACC and pACC images in Figure 1(A) of Ref.2 are similar to the ACC and pACC images in Figure 1(a) of Ref.4, respectively.
Moreover, the leftside 6 bands of these two images are similar to the ACC and p-ACC images in Figure 2(A) of Ref.1.
__________________
References
1,
J Atheroscler Thromb. 2010;17(5):503-9. Epub 2010 Feb 24.
Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo.
Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K.
2,
Cardiovasc Res. 2009 Jan 1;81(1):133-9. Epub 2008 Aug 14.
Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.
Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S, Satoh H, Akimoto K, Kasai K.
3,
Hypertens Res. 2009 Sep;32(9):765-9. Epub 2009 Jul 10.
Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K.
4.
Am J Hypertens. 2008 Apr;21(4):451-7. Epub 2008 Feb 7.
Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
Suzuki K, Uchida K, Nakanishi N, Hattori Y.
Sincerely yours,
Juuichi Jigen
E-mail: 11jigen@mail.goo.ne.jp
Life Sciences誌からの返信メール
件名
Re: Allegations of fabrication and falsification (Life Sciences 2008;82:884-91).
送信者
Frank Porreca
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
CC
Kanter-Schlifke, Irene (ELS-AMS) ; Kisthardt, Christine K - (kisthdt)
日時
2011年02月04日 00:44:29
Dear Dr. Jigen,
thank-you for bringing this to our attention. We will investigate
this and be back in touch shortly.
Sincerely,
Frank Porreca
At 01:10 AM 2/3/2011, you wrote:
>Dear Dr. Porreca,
>
>Please investigate fraudulent data of the article $B!H(BPPARalpha
>activators upregulate eNOS activity and inhibit cytokine-induced
>NF-kappaB activation through AMP-activated protein kinase
>activation.$B!I(B Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori
>Y., published in Life Sciences (2008 Apr 9;82(15-16):884-91). You
>can find fabricated (falsified) Figure 1(A),(B) and Figure
>5(A),(B),(C) : namely,
>
>(1)
>The Phospho-IkB-alpha image in Figure 4(A) of Ref.2 is similar to
>the Phospho-IkB-alpha image in Figure 5(A) of Ref.3
>and the Phospho-IkBa image in Figure 3(A) of Ref.4
>and the Phospho IkB-alpha image in Figure 6(A) of Ref.5.
>
>(2)
>The IkB-alpha image in Figure 4(B) of Ref.2 is similar to
>the IKB-alpha image in Figure 5(B) of Ref.3
>and the IkBa image in Figure 3(B) of Ref.4
>and the leftside 4 bands of the ONOO-IkB-alpha image in Figure 6(A) of Ref.5.
>
>(3)
>The GST-Ikb-alpha image of top panel in Figure 4(C) of Ref.1 is
>similar to both GST-Ikb-alpha image of top panel in Figure4(C) of
>Ref.2 and IkB-alpha image of top panel in Figure 5(C) of Ref.3
>
>
>(4)
>The IKKalpha/beta image in Figure 4(C) of Ref.2 is similar to both
>the ACC image in Figure 1(A) of Ref.3 and the IKKalpha/beta image in
>Figure 5(C) of Ref.3.
>
>(5)
>The GST-Ikb-alpha image of bottom panel in Figure 4(C) of Ref.2 is
>similar to GST-Ikb-alpha image of bottom panel in Figure4(C) of
>Ref.3. Moreover, these two images are similar to both the left-right
>reversal of the Akt image in Figure 1(A) of Ref.1 and the
>upside-down + left-right reversal of the GST-Ikb-alpha image of
>bottom panel in Figure4(C) of Ref.1
>
>(6)
>The GST-IkB-alpha image, bottom panel in Figure 4(C) of Ref.2 is
>similar to the Akt image in Figure 1(A) of Ref.3.
>
>(7)
>The p-AKT image in Figure 1(A) of Ref.3 is similar to the p-ACC
>image in Figure 1(B) of Ref.3
>
>(8)
>The IkB-alpha image in Figure 5(A) of Ref.3 is similar to both the
>IkB-a image in Figure 3(A) of Ref.4 and the IkB-alpha image in
>Figure 6(A) of Ref.5.
>
>(9)
>The AMPK and pAMPK images in Figure 1(A) of Ref.1 are similar to the
>AMPK and pAMPK images in Figure 1(A) of Ref.3.
>
>(10)
>The p-AKT image in Figure 1(A) of Ref.1 is similar to the p-Akt
>image in Figure 1(A) of Ref.3.
>
>(11)
>The eNOS image in Figure 1(A) of Ref.1 is similar to the eNOS image
>in Figure 1(A) of Ref.3.
>
>
>
>__________________
>
>References
>
>1,
>Metabolism. 2010 Jun 25. [Epub ahead of print]
>Fenofibrate suppresses microvascular inflammation and apoptosis
>through adenosine monophosphate-activated protein kinase activation.
>Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K.
>
>2,
>Cardiovasc Res. 2009 Jan 1;81(1):133-9. Epub 2008 Aug 14.
>Cilostazol inhibits cytokine-induced nuclear factor-kappaB
>activation via AMP-activated protein kinase activation in vascular
>endothelial cells.
>Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S,
>Satoh H, Akimoto K, Kasai K.
>
>3,
>Life Sci. 2008 Apr 9;82(15-16):884-91. Epub 2008 Feb 16.
>PPARalpha activators upregulate eNOS activity and inhibit
>cytokine-induced NF-kappaB activation through AMP-activated protein
>kinase activation.
>Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y.
>
>
>4,
>Hypertension. 2006 Jun;47(6):1183-8. Epub 2006 Apr 24.
>Metformin inhibits cytokine-induced nuclear factor kappaB activation
>via AMP-activated protein kinase activation in vascular endothelial cells.
>Hattori Y, Suzuki K, Hattori S, Kasai K.
>
>
>5,
>Cardiovasc Res. 2004 Jul 1;63(1):31-40.
>NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to
>rationalize cytoprotective and cytotoxic actions attributed to NO.
>Hattori Y, Kasai K, Gross SS.
>
>
>
>Sincerely yours,
>
>Juuichi Jigen
>E-mail: 11jigen@mail.goo.ne.jp
>
>
>
>
>
Biochimica et Biophysica Acta誌からの返信メール
件名
Re: Allegations of fabrication and falsification
送信者
Dennis Vance
宛先
Juuichi Jigen <11jigen@mail.goo.ne.jp>
CC
Jeffrey Keller ; Adriaan FA (ELS-AMS) Klinkenberg
日時
2011年02月03日 01:35:29
添付
J Cardiovasc Pharmacol. 2004 43 209-13.pdf (583k)attach1 (1k)
Dear Dr. Jigen:
Thanks for your email. I have looked at the two figures and agree that the top panels in the two Figures seem to be identical but I am not so sure the bottom panels are the same. I shall write to Dr. Hattori and ask for an explanation. I will let you know his reply and any action we might take.
Sincerely yours,
Dennis Vance, PhD
Distinguished University Professor
Editor-in-Chief, BBA
Scientist of the Alberta Heritage Foundation for Medical Research
Chair, Board of Directors, Deuel Conference on Lipids
Department of Biochemistry and Group on the Molecular and Cell Biology of Lipids
School of Molecular and Systems Medicine
328 Heritage Medical Research Centre
University of Alberta
Edmonton, Alberta T6G 2S2 Canada
phone: 780-492-8286
Fax: 780-492-3383
email: dennis.vance@ualberta.ca
Journal of Cardiovascular Pharmacology誌からの返信メール
件名
Re: RE: Allegations of fabrication and falsification
送信者
Juuichi Jigen <11jigen@mail.goo.ne.jp>
宛先
Emily.Hurd@wolterskluwer.com
添付
BBA2004.pdf (613k)JCP2004.pdf (583k)
Dear Dr. Hurd,
I am sorry for your inconvenience.
Now, I send new attachments.
Please compare Figure 3's top panel of JCP2004 article and Figure 5's top panel of BBA2004 article.
Sincerely yours,
Juuichi Jigen
----- Original Message -----
> Dear Dr. Jigen:
>
> We are not able to open the files attached to this email either. Please
> send new attachments.
>
> Kind Regards,
> Emily Hurd
>
> Emily Hurd
> Managing Editor, Journal of Cardiovascular Pharmacology
> Wolters Kluwer Health Medical Research
>
> tel (978) 979-1111
> emily.hurd@wolterskluwer.com
>
> Confidentiality Notice: This email and its attachments (if any) contain
> confidential information of the sender. The information is intended only
> for the use by the direct addressees of the original sender of this
> email. If you are not an intended recipient of the original sender (or
> responsible for delivering the message to such person), you are hereby
> notified that any review, disclosure, copying, distribution or the
> taking of any action in reliance of the contents of and attachments to
> this email is strictly prohibited. If you have received this email in
> error, please immediately notify the sender at the address shown herein
> and permanently delete any copies of this email (digital or paper) in
> your possession.
>
>
> -----Original Message-----
> From: Juuichi Jigen [mailto:11jigen@mail.goo.ne.jp]
> Sent: Wednesday, February 02, 2011 9:28 AM
> To: Hurd, Emily; Sollenberger, Jennifer; Hee, Laurie
> Subject: Allegations of fabrication and falsification
>
> Please investigate fraudulent data of the article "Disruption of the
> actin cytoskeleton up-regulates iNOS expression in vascular smooth
> muscle cells." by Hattori Y, Kasai K. published in J Cardiovasc
> Pharmacol. (2004 Feb;43(2):209-13.). You can find the fabricated
> (falsified) Figure 3 : namely, Figure 3 of the above article [J
> Cardiovasc Pharmacol. (2004 Feb;43(2):209-13.)] is identical to Figure 5
> of another article [Biochim Biophys Acta. (2004 Aug 4;1689(3):267-72.)].
>
>
> References
> 1
> J Cardiovasc Pharmacol. 2004 Feb;43(2):209-13.
> Disruption of the actin cytoskeleton up-regulates iNOS expression in
> vascular smooth muscle cells.
> Hattori Y, Kasai K.
> http://www.ncbi.nlm.nih.gov/pubmed/14716207
>
> 2
> Biochim Biophys Acta. 2004 Aug 4;1689(3):267-72.
> Statin blocks Rho/Rho-kinase signalling and disrupts the actin
> cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide
> synthesis in vascular smooth muscle cells.
> Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y.
>
Diabetes, Obesity and Metabolism誌からの返信メール
件名
FW: Diab. Obes. Metab. 2009; 11: 143-149
送信者
Susan Lane
宛先
11jigen@mail.goo.ne.jp
日時
2011年02月03日 23:11:21
From: Richard Donnelly [mailto:Richard.Donnelly@nottingham.ac.uk]
Sent: 03 February 2011 11:04
To: 11jigen@mail.goo.n.ejp
Cc: Susan Lane
Subject: Diab. Obes. Metab. 2009; 11: 143-149
Dear Dr Jigen:
Thank you for your Email concerning a paper published by Jojima et al in Diab. Obes. Metab.
Research misconduct is something that concerns all of us, but the responsibility for investigating allegations of research misconduct lies with the university that employs the authors and any sponsor that funded the research. Most, if not all, universities have clear internal policies and procedures for investigating allegations of research misconduct.
You should, therefore, direct your concerns to the relevant Dean or principal of Dokkyo University School of Medicine. If the institution, as part of their investigation, requires information from the Journal, I will be happy to assist. Furthermore, the journal would take appropriate action only on the advice of an institutional committee or head, following the conclusion of their internal investigation.
Sincerely:
Prof. Richard Donnelly MD, PhD, FRCP, FRACP
Editor, Diabetes, Obesilty and Metabolism
